(2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov
(1995). A: NMRPipe: a multidimensional spectral processing system based on UNIX pipes.
(1996). AJ: Automated docking of flexible ligands: applications of AutoDock.
Biological Magnetic Resonance Data Bank
(2000). BJV: DNA polymerase beta and mammalian base excision repair. Cold Spring Harb Symp Quant Biol
(2001). Caldecott KW: XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell
(2003). Campbell ID: Studies of protein-ligand interactions by NMR. Biochem Soc Trans
(2007). Canitrot Y: Involvement of DNA polymerase mu in the repair of a specific subset of DNA double-strand breaks in mammalian cells. Nucleic Acids Res
(2006). Canitrot Y: The DNA polymerase lambda is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. Nucleic Acids Res
(2005). Cazaux C: Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol
(1999). Cells deficient in DNA polymerase beta are hypersensitive to alkylating agentinduced apoptosis and chromosomal breakage. Cancer Res
(1988). Clore GM: Three-dimensional NMR spectroscopy of a protein in solution. Nature
(1994). Crystal structure of rat DNA polymerase beta: evidence for a common polymerase mechanism. Science
(1994). DE: Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
(2005). Determination of proteinligand binding affinity by NMR: observations from serum albumin model systems. Magn Reson Chem
(1995). DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA
(2000). E: DNA polymerase beta is required for efficient DNA strand break repair induced by methyl methanesulfonate but not by hydrogen peroxide. Nucleic Acids Res
(2001). Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene
(1996). Fesik SW: Discovering highaffinity ligands for proteins: SAR by NMR. Science
(1999). Fesik SW: High-throughput nuclear magnetic resonance-based screening.
(1996). G: In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic.
Global Optimization by Simulated Annealing.
(1994). GP: Assignments of 1H, 15N, and 13C resonances for the backbone and side chains of the N-terminal domain of DNA polymerase beta. Determination of the secondary structure and tertiary contacts. Biochemistry
(2000). GP: Backbone dynamics and refined solution structure of the N-terminal domain of DNA polymerase beta. Correlation with DNA binding and dRP lyase activity.
(2004). GP: Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping.
(1996). GP: Three-dimensional solution structure of the N-terminal domain of DNA polymerase beta and mapping of the ssDNA interaction interface. Biochemistry
(1991). Gronenborn AM: Structures of larger proteins in solution: three- and four-dimensional heteronuclear NMR spectroscopy. Science
(2001). Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor.
(2004). Hübscher U: The DNA-polymerase-X family: controllers of DNA quality? Nat Rev Mol Cell Biol
(2007). ME: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol
(2008). Nucleic Acids Res
(2005). O'Connor MJ: The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst)
(1996). Ponting CP: The helix-hairpin-helix DNA-binding motif: a structural basis for non-sequence-specific recognition of DNA.
(2004). Saturation transfer difference NMR spectroscopy for identifying ligand epitopes and binding specificities. Ernst Schering Res Found Workshop
(1996). Sawaya MR: Characterization of the metal ion binding helix-hairpin-helix motifs in human DNA polymerase beta by X-ray structural analysis. Biochemistry
(2003). Schleyer PVR: How do ring currents affect (1)h NMR chemical shifts? Org Lett
(2000). SG: The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
(2006). SH: Activities and mechanism of DNA polymerase beta. Methods Enzymol
(1998). SH: Functional analysis of the amino-terminal 8-kDa domain of DNA polymerase beta as revealed by site-directed mutagenesis. DNA binding and 5'-deoxyribose phosphate lyase activities.
(2001). SH: Mammalian DNA beta-polymerase in base excision repair of alkylation damage. Prog Nucleic Acid Res Mol Biol
(1996). SH: Requirement of mammalian DNA polymerasebeta in base-excision repair.
(2000). SH: The lyase activity of the DNA repair protein betapolymerase protects from DNA-damage-induced cytotoxicity. Nature
(2006). Site-directed mutational analysis of structural interactions of low molecule compounds binding to the N-terminal 8 kDa domain of DNA polymerase beta. Biochem Biophys Res Commun
(1992). Sklenár V: Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.
(1997). The inhibitory action of fatty acids on DNA polymerase beta. Biochim Biophys Acta
(1998). The inhibitory effect of novel triterpenoid compounds, fomitellic acids, on DNA polymerase beta.
(2002). The PyMOL Molecular Graphics System.
(2004). Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol Biol